目的 探讨胃康胶囊联合泮托拉唑钠肠溶胶囊治疗消化性溃疡的临床疗效。方法 选取2019年5月—2020年10月在南阳市中心医院就诊的106例消化性溃疡患者，按照随机数字表法将所有患者分为对照组和治疗组，各有53例。对照组口服泮托拉唑肠溶胶囊，40 mg/次，1次/d。治疗组在对照组治疗的基础上口服胃康胶囊，1.2 g/次，3次/d。两组患者连续治疗6周。观察两组的临床疗效，采用视觉模拟评分法（VAS）对患者主观腹痛程度进行评估，检测两组治疗前后血清白细胞介素-17（IL-17）、白细胞介素-1β（IL-1β）、基质金属蛋白酶-9（MMP-9）、表皮生长因子（EGF）、血管内皮生长因子（VEGF）、转化生长因子-α（TGF-α）水平。结果 治疗后，治疗组的总有效率为94.34%，对照组总有效率为81.13%，组间对比有显著性意义（P<0.05）。治疗后，两组VAS评分显著降低（P<0.05），以治疗组VAS评分降低的更明显（P<0.05）。治疗后，两组的IL-17、IL-1β、MMP-9水平显著降低（P<0.05）；治疗组的IL-17、IL-1β、MMP-9水平低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的EGF、VEGF、TGF-α水平显著升高（P<0.05），以治疗组EGF、VEGF、TGF-α水平升高的更明显（P<0.05）。结论 胃康胶囊联合泮托拉唑钠肠溶胶囊可提高消化性溃疡的临床疗效，减轻患者腹痛程度，降低炎症因子，促进溃疡面愈合，且安全性良好。

Objective To investigate the clinical efficacy of Weikang Capsules combined with Pantoprazole Sodium Enteric Capsules in treatment of peptic ulcer. Methods Patients (106 cases) with peptic ulcer in Nanyang Central Hospital from May 2019 to October 2020 were randomly divided into control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Pantoprazole Sodium Enteric Capsules, 40 mg/time, once daily. Patients in the treatment group were po administered with Weikang Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacies were evaluated, and the curative effect of two groups was observed, the degree of subjective abdominal pain was evaluated by VAS, and the serum levels of IL-17, IL-1β, MMP-9, EGF, VEGF, and TGF-α were detected before and after treatment. Results After treatment, the total effective rates in the treatment group and control group were 94.34% and 81.13%, with significant difference between the two groups (P<0.05). After treatment, the VAS score of two groups were significantly decreased (P<0.05), and the VAS score of the treatment group was significantly lower than that of the control group (P<0.05). After treatment, the levels of IL-17, IL-1β, and MMP-9 in two groups were significantly decreased (P<0.05); and the levels of IL-17, IL-1β, and MMP-9 in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of EGF, VEGF, and TGF-α in two groups were significantly increased (P<0.05), and the levels of EGF, VEGF, and TGF-α in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Weikang Capsules combined with Pantoprazole Sodium Enteric Capsules can improve the curative effect of peptic ulcer, reduce the degree of abdominal pain, reduce inflammatory factors, and promote ulcer healing, with good safety.

R975

河南省科技发展计划项目（192102310326）